Any current/future new fundraising through debt or equity?

No explicit mention of any current or planned fundraising through debt or equity in the provided transcript. The company has a strong cash and cash equivalent position of Rs. 474.2 Crores as of June 30, 2023, which includes Rs. 130 Crores from IPO funds. Management expressed confidence in completing all planned capital expenditure (capex) of roughly Rs. 800-900 Crores over the next four years using internal accruals plus the existing cash balance. Annual capex is expected to be between Rs. 200 to 225 Crores in the near term. There are no indications of plans to raise new debt or equity; the co

Any current/future capex/capital investment/strategic investment?

Rainbow Children’s Medicare Limited plans to build roughly 930 beds over the next 4 years, with an overall capex of approximately Rs. 800 to 900 Crores, including the Gurugram land parcel. As of June 30, 2023, the company holds Rs.474 Crores cash, including Rs.130 Crores IPO funds, supporting the capex plan. Annual capex for FY2024 is expected to be between Rs. 200 to 225 Crores, higher than previous years due to opening 4 hospitals this year and 2 next year. Routine capex is modest, around Rs. 20 to 25 Crores annually; the majority of expenditure is on new projects. The capex spend is spread

Future growth expectations in sales/revenue/volumes?

Revenue for Q1 FY2024 grew by 21% to Rs.287.1 Crores driven by higher delivery numbers, pediatric surgical cases, and addition of 155 beds in 2 units. Outpatient and inpatient volumes increased by 11.6% and 13.9% respectively compared to FY2022. Occupancy in mature hospitals was robust at 47.6%, with new hospitals at 28.1%, expected to improve as they mature. Expansion plan includes adding 270 beds across locations, including new outpatient block with IVF facility in Hyderabad, and 60 beds in central Hyderabad. New hospitals in Bengaluru and Chennai expected to become EBITDA positive soon, wit

Future growth expectations in earnings/operating earnings/profits/EPS?

The company remains very positive about the year with significant project execution and improved operations (Page 16). EBITDA growth is expected despite some pressure from adding new beds and hospitals; new hospitals like those in Bengaluru and Chennai are expected to break even and grow profitability within 12-18 months (Page 13, 6). ARPOB (Average Revenue per Occupied Bed) growth is seen to sustain around 5-6% annually if ALOS (Average Length of Stay) remains stable (Page 11). Cash generation remains strong, supported by IPO funds and internal accruals, enabling completion of capital expendi

Rainbow Child.Q1 FY24Healthcare Services

Rainbow Child. Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,280P/E: 48.7Market Cap: ₹14.0K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

Revenue for Q1 FY2024 grew by 21% to Rs.287.1 Crores driven by higher delivery numbers, pediatric surgical cases, and addition of 155 beds in 2 units.
Outpatient and inpatient volumes increased by 11.6% and 13.9% respectively compared to FY2022.
Occupancy in mature hospitals was robust at 47.6%, with new hospitals at 28.1%, expected to improve as they mature.
Expansion plan includes adding 270 beds across locations, including new outpatient block with IVF facility in Hyderabad, and 60 beds in central Hyderabad.
New hospitals in Bengaluru and Chennai expected to become EBITDA positive soon, with spoke models taking 12-18 months to mature.
ARPOB growth is expected around 5-6% annually assuming stable average length of stay.
International business targeted to grow to 4% of overall business.
Management remains positive on project execution and operational growth for the year.

Margin guidance

Category 3

The company remains very positive about the year with significant project execution and improved operations (Page 16).
EBITDA growth is expected despite some pressure from adding new beds and hospitals; new hospitals like those in Bengaluru and Chennai are expected to break even and grow profitability within 12-18 months (Page 13, 6).
ARPOB (Average Revenue per Occupied Bed) growth is seen to sustain around 5-6% annually if ALOS (Average Length of Stay) remains stable (Page 11).
Cash generation remains strong, supported by IPO funds and internal accruals, enabling completion of capital expenditure plans without external borrowing (Page 14, 5).
The current EBITDA margin showed slight pressure due to new hospitals and increased expenses but is expected to improve as new units mature and revenue grows (Page 5, 13).
Overall, growth in revenue (~21% in Q1), EBITDA, and PAT (~7% in Q1) indicates a positive earnings trajectory ahead (Page 3).

See what Rainbow Child. management said on margin guidance — free account, 30 seconds.

Fundraise plans

No explicit mention of any current or planned fundraising through debt or equity in the provided transcript.
The company has a strong cash and cash equivalent position of Rs. 474.2 Crores as of June 30, 2023, which includes Rs. 130 Crores from IPO funds.
Management expressed confidence in completing all planned capital expenditure (capex) of roughly Rs. 800-900 Crores over the next four years using internal accruals plus the existing cash balance.
Annual capex is expected to be between Rs. 200 to 225 Crores in the near term.
There are no indications of plans to raise new debt or equity; the company aims to remain cash positive throughout its expansion.
The management emphasized reliance on internal cash generation and existing cash reserves without stating any need for fresh fundraising.

Order book

The transcript does not provide explicit details regarding the current or expected order book or pending orders for Rainbow Children’s Medicare Limited. However, relevant insights related to ongoing and planned projects include: - The company is in a phase of active project execution and expansion, with capital expenditure plans of ₹200-225 Crores principally aimed at new projects, not routine capex. - Recently acquired a land parcel in Gurugram for around ₹142 Crores, indicating expansion plans. - New hospital capacities are being added: 58 beds operationalized recently, with approximately 270 more beds planned for addition. - Expansion into new regions like Coimbatore in FY2025 is planned. - International business outreach is growing, targeting East Africa, neighboring countries, and Russia with expectations of international business contributing around 4% of total revenue this year. No specific order book numbers or pending orders are mentioned explicitly.

See what Rainbow Child. management said on order book — free account, 30 seconds.

Capex plans

Yes

Rainbow Children’s Medicare Limited plans to build roughly 930 beds over the next 4 years, with an overall capex of approximately Rs. 800 to 900 Crores, including the Gurugram land parcel.
As of June 30, 2023, the company holds Rs.474 Crores cash, including Rs.130 Crores IPO funds, supporting the capex plan.
Annual capex for FY2024 is expected to be between Rs. 200 to 225 Crores, higher than previous years due to opening 4 hospitals this year and 2 next year.
Routine capex is modest, around Rs. 20 to 25 Crores annually; the majority of expenditure is on new projects.
The capex spend is spread over the next four years, including the balance of the current year.
The company remains confident of being cash positive after completing all announced capex plans through internal accruals and existing cash reserves.

Track Rainbow Child. — get its next earnings analysis in your feed

How does Rainbow Child. rank vs peers in Healthcare Services?

Pro feature

ThisRainbow Child.

Rev 2Mar 3

See where Rainbow Child. sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Rainbow Child. rank in Healthcare Services?

Compare Rainbow Child. against every Healthcare Services company (Q1 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Rainbow Child.'s management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
Suven Life Sciences Ltd (Q1 FY22)
The provided pages of the Suven Life Sciences investor presentation do not contain any specific revenue, sales, or volume figures for any quarter. Key concall…
Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →